Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat

Journal of Assisted Reproduction and Genetics

Volumn 27, Issue 11, 2010, Pages 591-597

  Ting, Alison Y ^a,b   Petroff, Brian K ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Ovary; Rat; Toxicology

Indexed keywords

AFIMOXIFENE; CYCLOPHOSPHAMIDE; DIMETHYLBENZ[A]ANTHRACENE; DOXORUBICIN; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEMALE FERTILITY; LITTER SIZE; NEWBORN MORTALITY; NONHUMAN; OOCYTE; OVARIAN FOLLICULAR LOSS; OVARY CELL CULTURE; OVARY DISEASE; OVARY FOLLICLE; PRIMORDIAL GERM CELL; PRIORITY JOURNAL; RAT; REPRODUCTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FERTILITY; OOCYTES; OVARIAN FOLLICLE; OVARY; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

RATTUS;

EID: 78651337162     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10815-010-9463-y     Document Type: Article

References (40)

1. Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, et al. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod. 2008;23:2506-2512.
2. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin. 2005;55:211-228.
3. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169:123-131.
4. Pacey AA. Fertility issues in survivors from adolescent cancers. Cancer Treat Rev. 2007;33(7):646-55.
5. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353(1):64-73.
6. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormonereleasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52(2):365-372.
7. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044-1054.
8. Blumenfeld Z. GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabetes Obes. 2008;15(6):523-528.
9. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapyinduced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229-239.
10. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12(9):1055-1066.
11. Ting AY, Kimler BF, Fabian CJ, Petroff BK. Tamoxifen prevents premalignant changes of breast but not ovarian cancer in rats at high risk for both disease. Cancer Prev Res. 2008;1:546-554.
12. Kossoy G, Ben-Hur H, Elhayany A, Schneider DF, Kossoy N, Zusman I. Effects of tamoxifen and soluble tumor-associated antigens on ovarian structure in mammary tumor-bearing rats. Oncol Rep. 2005;14(5):1317-1321.
13. Geyer RP, Bleisch VR, Bryant JE, Robbins AN, Saslaw IM, Stare FJ. Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-1,2-benzanthracene. Cancer Res. 1951;11(6):474-478.
14. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet. 2001;28(4):355-360.
15. Borman SM, Christian PJ, Sipes IG, Hoyer PB. Ovotoxicity in female Fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic hydrocarbons: comparison through calculation of an ovotoxic index. Toxicol Appl Pharmacol. 2000;167(3):191-198.
16. Tsai-Turton M, Nakamura BN, Luderer U. Induction of apoptosis by 9, 10-dimethyl-1, 2-benzanthracene in cultured preovulatory rat follicles is preceded by a rise in reactive oxygen species and is prevented by glutathione. Biol Reprod. 2007;77(3):442-451.
17. Shiromizu K, Thorgeirsson SS, Mattison DR. Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6 N and DBA/2 N mice. Pediatr Pharmacol (New York). 1984;4(4):213-221.
18. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985;45(8):3651-3656.
19. Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ. 2006;13(9):1466-1474.
20. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15(10):1179-1185.
21. Oh SH, Miyoshi K, Funahashi H. Rat oocytes fertilized in modified rat 1-cell embryo culture medium containing a high sodium chloride concentration and bovine serum albumin maintain developmental ability to the blastocyst stage. Biol Reprod. 1998;59(4):884-889.
22. Perez GI, Tao XJ, Tilly JL. Fragmentation and death (a.k.a. apoptosis) of ovulated oocytes. Mol Hum Reprod. 1999;5(5):414-420.
23. Tilly JL. Ovarian follicle counts-not as simple as 1, 2, 3. Reprod Biol Endocrinol. 2003;1:11.
24. Stern JM, Strait T. Reproductive success, postpartum maternal behavior, and masculine sexual behavior of neonatally androgenized female hamsters. Horm Behav. 1983;17(2):208-224.
25. Jakubowski M, Terkel J. Female reproductive function and sexually dimorphic prolactin secretion in rats with lesions in the medial preoptic-anterior hypothalamic continuum. Neuroendocrinology. 1986;43(6):696-705.
26. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
27. Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El- Foudeh MO, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000;17(1):39-46.
28. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia. 1995;9(10):1631-1637.
29. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117(3):561-567.
30. Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, Giorda G, et al. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit. 2007;29(3):349-352.
31. Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980;40(11):4043-4047.
32. Hu X, Christian P, Sipes IG, Hoyer PB. Expression and redistribution of cellular Bad, Bax, and Bcl-X(L) protein is associated with VCD-induced ovotoxicity in rats. Biol Reprod. 2001;65(5):1489-1495.
33. Livera G, Petre-Lazar B, Guerquin MJ, Trautmann E, Coffigny H, Habert R. p63 null mutation protects mouse oocytes from radioinduced apoptosis. Reproduction. 2008;135(1):3-12.
34. Morita Y, Perez GI, Maravei DV, Tilly KI, Tilly JL. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol Endocrinol. 1999;13(6):841-850.
35. Thompson KE, Sipes IG, Greenstein BD, Hoyer PB. 17betaestradiol affords protection against 4-vinylcyclohexene diepoxideinduced ovarian follicle loss in Fischer-344 rats. Endocrinology. 2002;143(3):1058-1065.
36. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res. 1999;84(2):229-239.
37. Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16(4):309-314.
38. Fdarvari R, Boroujerdi M. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin. Cancer Chemother Pharmacol. 2005;56(5):497-509.
39. Shen LZ, Hua YB, Yu XM, Xu Q, Chen T, Wang JH, et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol. 2005;11(7):1060-1064.
40. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90-95.